Revelation Biosciences Stock EBITDA
| REVB Stock | USD 0.76 0.01 1.33% |
Revelation Biosciences fundamentals help investors to digest information that contributes to Revelation Biosciences' financial success or failures. It also enables traders to predict the movement of Revelation Stock. The fundamental analysis module provides a way to measure Revelation Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revelation Biosciences stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -95.2 K | -100 K |
Revelation | EBITDA |
Revelation Biosciences Company EBITDA Analysis
Revelation Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Revelation Biosciences EBITDA | (95.21 K) |
Most of Revelation Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revelation Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revelation EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Revelation Biosciences is extremely important. It helps to project a fair market value of Revelation Stock properly, considering its historical fundamentals such as EBITDA. Since Revelation Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Revelation Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Revelation Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Revelation Ebitda
Ebitda |
|
According to the company disclosure, Revelation Biosciences reported earnings before interest,tax, depreciation and amortization of (95,208). This is 100.01% lower than that of the Biotechnology sector and 100.1% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Revelation EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.Revelation Biosciences is currently under evaluation in ebitda category among its peers.
Revelation Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Revelation Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Revelation Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Revelation Biosciences' value.| Shares | Ubs Group Ag | 2024-06-30 | 27.3 K | Hrt Financial Llc | 2024-06-30 | 16.9 K | Tower Research Capital Llc | 2024-06-30 | 5 K | Royal Bank Of Canada | 2024-06-30 | 1.1 K | Bank Of America Corp | 2024-06-30 | 13.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Pom Investment Strategies, Llc | 2024-09-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Revelation Fundamentals
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 9.46 M | ||||
| Shares Outstanding | 4.29 M | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 2.31 % | ||||
| Number Of Shares Shorted | 41.24 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (95.21 K) | ||||
| Net Income | (120.25 K) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 5.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (7.29 M) | ||||
| Short Ratio | 0.69 X | ||||
| Earnings Per Share | (17.53) X | ||||
| Target Price | 12.75 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.24 M | ||||
| Total Asset | 12.21 M | ||||
| Retained Earnings | (25.47 M) | ||||
| Working Capital | 6.58 M | ||||
| Net Asset | 12.21 M |
About Revelation Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.53) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.